Question 1

What specific benefits do you think Tuvusertib and Niraparib could offer me?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) clinical trial (NCT04170153). Contact the study team or your healthcare provider for specific answers.

Question 2

How do these treatments compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) clinical trial (NCT04170153). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) clinical trial (NCT04170153). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatments and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) clinical trial (NCT04170153). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any dietary restrictions I need to follow while on these medications?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) clinical trial (NCT04170153). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or complications during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) clinical trial (NCT04170153). Contact the study team or your healthcare provider for specific answers.

What this study is about